Sign in or Register   Sign in or Register
  |  

Mouse Anti-MAGI2 (AA 519-628) Recombinant Antibody (CBFYM-1338) (CBMAB-M1497-FY)

This product is mouse antibody that recognizes MAGI2. The antibody CBFYM-1338 can be used for immunoassay techniques such as: ELISA, WB.
See all MAGI2 antibodies

Summary

Host Animal
Mouse
Specificity
Human
Clone
CBFYM-1338
Antibody Isotype
IgG1, k
Application
ELISA, WB

Basic Information

Immunogen
Recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.Immunogen sequence: PANSMVPPLA IMERPPPVMV NGRHNYETYL EYISRTSQSV PDITDRPPHS LHSMPTDGQL DGTYPPPVHD DNVSMASSGA TQAELMTLTI VKGAQGFGFT IADSPTGQRV
Specificity
Human
Antibody Isotype
IgG1, k
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
Epitope
AA 519-628

Target

Full Name
membrane associated guanylate kinase, WW and PDZ domain containing 2
Introduction
The protein encoded by this gene interacts with atrophin-1. Atrophin-1 contains a polyglutamine repeat, expansion of which is responsible for dentatorubral and pallidoluysian atrophy. This encoded protein is characterized by two WW domains, a guanylate kinase-like domain, and multiple PDZ domains. It has structural similarity to the membrane-associated guanylate kinase homologue family.
Entrez Gene ID
9863
UniProt ID
Q86UL8
Alternative Names
Membrane Associated Guanylate Kinase, WW And PDZ Domain Containing 2; Membrane-Associated Guanylate Kinase Inverted 2; Atrophin-1-Interacting Protein 1; Atrophin-1-Interacting Protein A; MAGI-2; AIP-1; AIP1; Membrane-Associated Guanylate Kinase, WW And PDZ Domain-Containing Protein 2
Function
Seems to act as scaffold molecule at synaptic junctions by assembling neurotransmitter receptors and cell adhesion proteins. May play a role in regulating activin-mediated signaling in neuronal cells. Enhances the ability of PTEN to suppress AKT1 activation. Plays a role in nerve growth factor (NGF)-induced recruitment of RAPGEF2 to late endosomes and neurite outgrowth.
Biological Process
Cellular response to nerve growth factor stimulusISS:UniProtKB
Glomerular visceral epithelial cell developmentISS:UniProtKB
Negative regulation of activin receptor signaling pathwayISS:UniProtKB
Negative regulation of cell migrationISS:UniProtKB
Negative regulation of cell population proliferationISS:UniProtKB
Negative regulation of protein kinase B signalingManual Assertion Based On ExperimentIDA:UniProtKB
Nerve growth factor signaling pathwayISS:UniProtKB
Nervous system developmentIEA:UniProtKB-KW
Planar cell polarity pathway involved in axis elongation1 PublicationNAS:UniProtKB
Positive regulation of neuron projection developmentISS:UniProtKB
Positive regulation of phosphoprotein phosphatase activityManual Assertion Based On ExperimentIDA:UniProtKB
Positive regulation of receptor internalizationManual Assertion Based On ExperimentIDA:UniProtKB
Receptor clusteringISS:UniProtKB
Signal transductionManual Assertion Based On ExperimentIBA:GO_Central
SMAD protein signal transductionISS:UniProtKB
Cellular Location
Cytoplasm
Late endosome
Cell junction, synapse, synaptosome
Cell membrane By Similarity; Peripheral membrane protein
Localized diffusely in the cytoplasm before nerve growth factor (NGF) stimulation. Recruited to late endosomes after NGF stimulation. Membrane-associated in synaptosomes (By similarity).
Involvement in disease
Nephrotic syndrome 15 (NPHS15):
A form of nephrotic syndrome, a renal disease clinically characterized by severe proteinuria, resulting in complications such as hypoalbuminemia, hyperlipidemia and edema. Kidney biopsies show non-specific histologic changes such as focal segmental glomerulosclerosis and diffuse mesangial proliferation. NPHS15 is an autosomal recessive form with onset in the first months of life. Disease severity is variable. Some patients show rapid progression to end-stage renal failure.

Xu, Z., Chen, Z., Peng, M., Zhang, Z., Luo, W., Shi, R., ... & Hong, Y. (2022). MicroRNA MiR-490-5p suppresses pancreatic cancer through regulating epithelial-mesenchymal transition via targeting MAGI2 antisense RNA 3. Bioengineered, 13(2), 2673-2685.

Xu, X., Yuan, X., Ni, J., Guo, J., Gao, Y., Yin, W., ... & Zhang, J. (2021). MAGI2‐AS3 inhibits breast cancer by downregulating DNA methylation of MAGI2. Journal of cellular physiology, 236(2), 1116-1130.

Kai-Xin, L., Cheng, C., Rui, L., Zheng-Wei, S., Wen-Wen, T., & Peng, X. (2021). Roles of lncRNA MAGI2-AS3 in human cancers. Biomedicine & Pharmacotherapy, 141, 111812.

Xue, C., Li, G., Lu, J., Luo, J., & Jia, J. (2021). Novel insights for lncRNA MAGI2-AS3 in solid tumors. Biomedicine & Pharmacotherapy, 137, 111429.

Yamada, H., Shirata, N., Makino, S., Miyake, T., Trejo, J. A. O., Yamamoto-Nonaka, K., ... & Asanuma, K. (2021). MAGI-2 orchestrates the localization of backbone proteins in the slit diaphragm of podocytes. Kidney International, 99(2), 382-395.

Zhang, J., & Wang, R. (2021). Deregulated lncRNA MAGI2-AS3 in Alzheimer's disease attenuates amyloid-β induced neurotoxicity and neuroinflammation by sponging miR-374b-5p. Experimental Gerontology, 144, 111180.

Li, D., Wang, J., Zhang, M., Hu, X., She, J., Qiu, X., ... & Qin, S. (2020). LncRNA MAGI2-AS3 is regulated by BRD4 and promotes gastric cancer progression via maintaining ZEB1 overexpression by sponging miR-141/200a. Molecular Therapy-Nucleic Acids, 19, 109-123.

Ren, H., Li, Z., Tang, Z., Li, J., & Lang, X. (2020). Long noncoding MAGI2‐AS3 promotes colorectal cancer progression through regulating miR‐3163/TMEM106B axis. Journal of cellular physiology, 235(5), 4824-4833.

Yin, Z., Ma, T., Yan, J., Shi, N., Zhang, C., Lu, X., ... & Jian, Z. (2019). LncRNA MAGI2‐AS3 inhibits hepatocellular carcinoma cell proliferation and migration by targeting the miR‐374b‐5p/SMG1 signaling pathway. Journal of cellular physiology, 234(10), 18825-18836.

Pu, J., Wang, J., Wei, H., Lu, T., Wu, X., Wu, Y., ... & Lu, Y. (2019). lncRNA MAGI2-AS3 prevents the development of HCC via recruiting KDM1A and promoting H3K4me2 demethylation of the RACGAP1 promoter. Molecular Therapy-Nucleic Acids, 18, 351-362.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-MAGI2 (AA 519-628) Recombinant Antibody (CBFYM-1338)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare